ATE233262T1 - Pcp-rezeptor-liganden und deren verwendung - Google Patents

Pcp-rezeptor-liganden und deren verwendung

Info

Publication number
ATE233262T1
ATE233262T1 AT90906688T AT90906688T ATE233262T1 AT E233262 T1 ATE233262 T1 AT E233262T1 AT 90906688 T AT90906688 T AT 90906688T AT 90906688 T AT90906688 T AT 90906688T AT E233262 T1 ATE233262 T1 AT E233262T1
Authority
AT
Austria
Prior art keywords
receptor ligands
disease
treatment
pcp receptor
iddc
Prior art date
Application number
AT90906688T
Other languages
English (en)
Inventor
Eckard Weber
John Keana
Peter Barmettler
Original Assignee
Oregon State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon State filed Critical Oregon State
Application granted granted Critical
Publication of ATE233262T1 publication Critical patent/ATE233262T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT90906688T 1989-04-14 1990-04-13 Pcp-rezeptor-liganden und deren verwendung ATE233262T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/337,858 US5011834A (en) 1989-04-14 1989-04-14 PCP receptor ligands and the use thereof
PCT/US1990/002083 WO1990012575A1 (en) 1989-04-14 1990-04-13 Pcp receptor ligands and the use thereof

Publications (1)

Publication Number Publication Date
ATE233262T1 true ATE233262T1 (de) 2003-03-15

Family

ID=23322317

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90906688T ATE233262T1 (de) 1989-04-14 1990-04-13 Pcp-rezeptor-liganden und deren verwendung

Country Status (8)

Country Link
US (1) US5011834A (de)
EP (1) EP0470127B1 (de)
JP (1) JP3346562B2 (de)
AT (1) ATE233262T1 (de)
AU (1) AU643205B2 (de)
CA (1) CA2050284C (de)
DE (1) DE69034043D1 (de)
WO (1) WO1990012575A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688789A (en) * 1989-04-14 1997-11-18 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon PCP receptor ligands and the use thereof
US5196415A (en) * 1989-05-09 1993-03-23 The United States Of America As Represented By The Department Of Health And Human Services 5-aminocarbonyl-5H-dibenzo[a.d]cyclohepten-5,10-imines for treatment of epilepsy and cocaine addiction
US5262568A (en) * 1990-03-02 1993-11-16 State Of Oregon Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
US5847006A (en) * 1991-02-08 1998-12-08 Cambridge Neuroscience, Inc. Therapeutic guanidines
US5508401A (en) * 1991-02-20 1996-04-16 American Home Products Corporation Substituted dibenzo[a,d]cycloheptene NMDA antagonists
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
WO1993025203A1 (en) * 1992-06-17 1993-12-23 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of treating and protecting against central nervous system ischemia, hypoxia, degeneration, and trauma with a 5-aminocarbonyl-sh-dibenzo[a,d]cyclohepten-5,10-imine
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
ES2204920T3 (es) * 1993-05-27 2004-05-01 Cenes Limited Guanidinas substituidas terapeuticas.
AU705487B2 (en) * 1993-11-23 1999-05-20 Cambridge Neuroscience, Inc. Therapeutic substituted guanidines
US7351743B1 (en) 1994-02-03 2008-04-01 Wyeth Therapeutic guanidines
WO1995020950A1 (en) 1994-02-03 1995-08-10 Cambridge Neuroscience, Inc. Therapeutic guanidines
US6787569B1 (en) 1994-02-03 2004-09-07 Cambridge Neuroscience, Inc. Therapeutic guanidines
US6143791A (en) * 1994-02-03 2000-11-07 Cambridge Neuroscience, Inc. Therapeutic guanidines
EP1203761B1 (de) 1994-10-21 2005-01-19 Nps Pharmaceuticals, Inc. Kalzium-Rezeptor aktive Verbindungen
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
TW427978B (en) * 1996-02-03 2001-04-01 Hoffmann La Roche Tetrahydroisoquinoline derivatives
US6025355A (en) 1997-05-19 2000-02-15 Cambridge Neuroscience, Inc. Pharmaceutically active compounds and methods of use
DK0907631T3 (da) 1996-05-01 2003-09-22 Nps Pharma Inc Uorganiske ionreceptoraktive forbindelser
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US6242198B1 (en) 1996-07-25 2001-06-05 Cambridge Neuroscience, Inc. Methods of treatment of eye trauma and disorders
US6756389B2 (en) * 1996-08-09 2004-06-29 Cambridge Neuroscience, Inc. Pharmaceutically active compounds and methods of use
PL332413A1 (en) 1996-09-27 1999-09-13 Guilford Pharm Inc Compositions containing inhibitors of naaladase as well as methods of treating glutamatic anomaly and influencing neuronic functions among animals
WO1998041223A1 (en) * 1997-03-20 1998-09-24 The Regents Of The University Of California N-methyl-d-aspartate receptor channel blockers and method for identifying such
US7115508B2 (en) * 2004-04-02 2006-10-03 Applied-Materials, Inc. Oxide-like seasoning for dielectric low k films
AU2017286217B2 (en) * 2016-06-13 2021-06-24 Assistance Publique - Hopitaux De Paris (Aphp) Novel dizocilpine derivatives as peripheral NMDA receptor antagonists

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1035141B (de) * 1955-07-21 1958-07-31 Dr Edmund Waldmann Verfahren zur Herstellung von 2,3,6,7-Dibenzo-cyclo-heptadien-(2,6)-1,5-methyleniminen
US3361767A (en) * 1966-04-04 1968-01-02 American Home Prod 10, 5(epoxymethano)-10, 11-dihydro-5h-dibenzo[a, d]cyclohepten-13-one and derivatives
CH496716A (de) * 1966-04-22 1970-09-30 Wander Ag Dr A Verfahren zur Herstellung von 5H-Dibenzo(a,d)cyclohepten-Derivaten
CH461475A (de) * 1966-04-22 1968-08-31 Wander Ag Dr A Verfahren zur Herstellung von Cycloheptenderivaten
US3458518A (en) * 1966-11-01 1969-07-29 American Home Prod 10,5-(iminomethano)-10,11-dihydro-5h-dibenzo(a,d)cyclohepten-11-ones
CH485654A (de) * 1967-04-06 1970-02-15 Wander Ag Dr A Verfahren zur Herstellung von 10,11-Dihydro-5H-dibenzo(a,d)-cyclohepten-Derivaten
US3542787A (en) * 1968-06-25 1970-11-24 American Home Prod 10,11-dihydro-5,10-(iminomethano)-5h-dibenzo(a,d)cyclohepten-13-imine
US3597433A (en) * 1968-08-19 1971-08-03 Ayerst Mckenna & Harrison 10,11 - dihydro - 5,10 - (iminomethano)-5h-dibenzo(a,d)cycloheptene and derivatives thereof
US3641038A (en) * 1968-10-29 1972-02-08 Ayerst Mckenna & Harrison 10,11-dihydro - 10 5 - (iminomethano)-5h-dibenzo( ad)cyclohepten - 10 01acid addition salts the reofand process
NL7007464A (de) * 1969-05-30 1970-12-02
US3812119A (en) * 1969-11-21 1974-05-21 Ciba Geigy Corp Dibenzocycloheptenes
US3716541A (en) * 1970-07-23 1973-02-13 Ayerst Mckenna & Harrison Substituted derivatives of 10,11-dihydro-5,10-(iminomethano)-5h-dibenzo, cycloheptenes and preparation thereof
BE794904A (fr) * 1972-02-04 1973-08-02 Roussel Uclaf Nouveaux derives du dibenzocycloheptene et leur preparation
US4052508A (en) * 1974-08-19 1977-10-04 Merck & Co., Inc. Heterocyclic dihydroanthracen imines
US4064139A (en) * 1975-04-07 1977-12-20 Merck & Co., Inc. Substituted 9,10-dihydroanthracen-9,10-imines
FR2383946A1 (fr) * 1977-03-16 1978-10-13 Enzypha Nouveau derive de l'ajmaline, son procede de preparation et son application en therapeutique
US4374838A (en) * 1977-09-19 1983-02-22 Merck & Co., Inc. Dibenzo[a,d]cycloocten-5,12-(and 6,12)-imines
US4399141A (en) * 1977-09-19 1983-08-16 Merck & Co., Inc. 5-Alkyl or hydroxyalkyl substituted-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imines and anticonvulsant use thereof
US4232158A (en) * 1979-06-04 1980-11-04 Merck & Co., Inc. 10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imines
US4390141A (en) * 1981-05-26 1983-06-28 Webster Jerald H Strap winding mechanism
US4465677A (en) * 1982-07-14 1984-08-14 Smithkline Beckman Corporation Pharmaceutical compositions and method of producing alpha2 antagonism
JPS5936675A (ja) * 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
GB8600783D0 (en) * 1986-01-14 1986-02-19 Merck Sharp & Dohme N-methyl-d-aspartate receptor antagonists
US4762828A (en) * 1987-06-10 1988-08-09 Pennwalt Corporation 1,2,4-triazolo[4,3-d]-4-azatricyclo-[4.3.1.13,8 ]undecane and 3-substituted derivatives, and intermediates thereof

Also Published As

Publication number Publication date
US5011834A (en) 1991-04-30
CA2050284C (en) 2000-11-14
DE69034043D1 (de) 2003-04-03
AU5448890A (en) 1990-11-16
EP0470127A1 (de) 1992-02-12
EP0470127A4 (en) 1992-06-24
JPH05501540A (ja) 1993-03-25
JP3346562B2 (ja) 2002-11-18
WO1990012575A1 (en) 1990-11-01
AU643205B2 (en) 1993-11-11
EP0470127B1 (de) 2003-02-26
CA2050284A1 (en) 1990-10-15

Similar Documents

Publication Publication Date Title
DE69034043D1 (de) Pcp-rezeptor-liganden und deren verwendung
EP0552256A4 (de)
MY143051A (en) Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
RU93051176A (ru) Производные роданина, способ их получения, фармацевтическая композиция, использование в качестве гипогликемических агентов и для лечения болезни альцгеймера
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
BR9408378A (pt) Composto sal farmaceuticamente aceitável composição farmacêutica e processos para o tratamento de um paciente que sofreu um derrame e que sofre de uma condição de perda progressiva de função de sistema nervoso central e para melhorar os efeitos colaterais causados em um paciente por tratamento antineoplástico de doença que produz danos oxidativos
IT1241996B (it) Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione.
DE69329400D1 (de) L-Dopa Ester enthaltende Zusammensetzung
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
DE69133065D1 (de) Tri- und tetra-substituierte guanidine und deren verwendung als antagonisten von exzitatorischen aminosäuren
IL107134A0 (en) Pharmaceutical compositions for the treatment of parkinson's disease
IL86423A0 (en) Pharmaceutical compositions for the treatment of alzheimer's disease
HUT61567A (en) Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate
NO973342D0 (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av cerebrale degenerative sykdommer
IL118833A (en) Sertraline for use as a medicament in the treatment of post-myocardial infarction patients
ZA924128B (en) New combination preparations for treatment of Parkinson's disease.
PT95698A (pt) Processo para a preparacao de composicoes farmaceuticas contendo aril-alquilamidas utilizadas no tratamento de doencas neurodegenarativas
MX9303074A (es) Uso de la (e)-2-(p-fluorofenetil)-3-fluoroalilamina en el tratamiento de la enfermedad de elzheimer.
ATE192650T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
DK0950053T3 (da) Hidtil ukendte benzoylalkyl.1,2,3,6-tetrahydropyridinderivater
PT95825A (pt) Processo para a preparacao de composicoes farmaceuticas para a administracao transdermica contendo 2-amino-6-n-propilamino-4,5,6,7-tetra-hidrobenzotriazol
KR930703003A (ko) 피부질환치료용 제약 조성물
ZA921101B (en) Use of tetra: Hydro-thieno-pyrido-indole derivatives for the prepartion of a medicine for the treatment of skin disorders.
CA2033975A1 (en) Use of .beta.-receptor blocking agents
DE69131521D1 (de) Alpha-Ergocryptine enthaltende pharmazeutische Zusammensetzungen mit nervenschützender Wirkung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties